Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
Not Applicable
Recruiting
- Conditions
- Alzheimer Disease
- Interventions
- Device: Brain MRIOther: neuropsychological evaluationBiological: Blood
- Registration Number
- NCT02811653
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Brief Summary
In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 155
Inclusion Criteria
-
Patients
- Age between 40 and 85
- French mother tongue
- Consulting at the Amiens Memory Resource and Research Centre (CMRR) for:
- MCI, according to Albert et al.'s criteria (Albert et al., 2011)
- Mild dementia (MMSE>20) due to AD, according to McKhann's criteria (McKhann et al., 2011).
- Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005).
- Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011).
- Social security coverage
-
Healthy controls
- Healthy age and gender matched volunteers will be recruited into the study from the general population.
Exclusion Criteria
-
Reading or writing difficulties related to a learning disorder or illiteracy.
-
A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure):
- NYHA stage IV dyspnoea.
- respiratory impairment requiring oxygen therapy.
- liver impairment.
- kidney failure, progressing neoplastic disease, or past or present alcohol abuse.
-
Past or present neurological disorders other than those having prompted consultation in the Memory Clinic:
- stroke.
- meningitis or encephalitis.
- severe head injury.
- sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments).
- epilepsy (requiring ongoing treatment),
- psychiatric disorders (other than treated depression).
- treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state.
-
Impossibility to perform a neuropsychological evaluation or brain MRI.
-
Withdrawal from the study at any time, if desired.
-
Pregnancy
-
Contra-indication to MRI:
- nerve stimulators
- cochlear implants
- ferromagnetic foreign bodies close to nervous structures in the eye or brain
- cerebral shunts
- dental appliances
-
Legal guardianship or incarceration.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description control neuropsychological evaluation Healthy age- and gender-matched volunteers will be recruited into the study from the general population. Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation Alzheimer disease neuropsychological evaluation Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation control Blood Healthy age- and gender-matched volunteers will be recruited into the study from the general population. Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation Alzheimer disease Blood Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation Alzheimer disease Brain MRI Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation control Brain MRI Healthy age- and gender-matched volunteers will be recruited into the study from the general population. Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
- Primary Outcome Measures
Name Time Method median SRT (simple reaction time) to a stimulus (in milliseconds) Day 0
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Amiens
🇫🇷Amiens, France